PL1644412T3 - Modyfikowane fragmenty Fab przeciwciała - Google Patents

Modyfikowane fragmenty Fab przeciwciała

Info

Publication number
PL1644412T3
PL1644412T3 PL04743158T PL04743158T PL1644412T3 PL 1644412 T3 PL1644412 T3 PL 1644412T3 PL 04743158 T PL04743158 T PL 04743158T PL 04743158 T PL04743158 T PL 04743158T PL 1644412 T3 PL1644412 T3 PL 1644412T3
Authority
PL
Poland
Prior art keywords
fab fragments
modified antibody
antibody fab
modified
fragments
Prior art date
Application number
PL04743158T
Other languages
English (en)
Other versions
PL1644412T5 (pl
Inventor
David Paul Humphreys
Sam Philip Heywood
Original Assignee
Ucb Biopharma Sprl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33566544&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL1644412(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB0315457.2A external-priority patent/GB0315457D0/en
Priority claimed from GB0319588A external-priority patent/GB0319588D0/en
Application filed by Ucb Biopharma Sprl filed Critical Ucb Biopharma Sprl
Publication of PL1644412T3 publication Critical patent/PL1644412T3/pl
Publication of PL1644412T5 publication Critical patent/PL1644412T5/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Surgery (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
PL04743158T 2003-07-01 2004-07-01 Modyfikowane fragmenty Fab przeciwciała PL1644412T5 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB0315457.2A GB0315457D0 (en) 2003-07-01 2003-07-01 Biological products
GB0319588A GB0319588D0 (en) 2003-08-20 2003-08-20 Biological products
EP04743158.0A EP1644412B2 (en) 2003-07-01 2004-07-01 Modified antibody fab fragments
PCT/GB2004/002810 WO2005003169A2 (en) 2003-07-01 2004-07-01 Modified antibody fab fragments

Publications (2)

Publication Number Publication Date
PL1644412T3 true PL1644412T3 (pl) 2016-02-29
PL1644412T5 PL1644412T5 (pl) 2019-01-31

Family

ID=33566544

Family Applications (1)

Application Number Title Priority Date Filing Date
PL04743158T PL1644412T5 (pl) 2003-07-01 2004-07-01 Modyfikowane fragmenty Fab przeciwciała

Country Status (14)

Country Link
US (1) US7989594B2 (pl)
EP (1) EP1644412B2 (pl)
JP (1) JP2007536898A (pl)
AU (1) AU2004253738A1 (pl)
CA (1) CA2527020A1 (pl)
CY (1) CY1116913T1 (pl)
DK (1) DK1644412T4 (pl)
ES (1) ES2551439T5 (pl)
HR (1) HRP20151252T4 (pl)
HU (1) HUE026278T2 (pl)
PL (1) PL1644412T5 (pl)
PT (1) PT1644412E (pl)
SI (1) SI1644412T2 (pl)
WO (1) WO2005003169A2 (pl)

Families Citing this family (167)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005051422A1 (en) 2003-11-21 2005-06-09 Celltech R & D Limited Method for the treatment of multiple sclerosis by inhibiting il-17 activity
GB0329825D0 (en) 2003-12-23 2004-01-28 Celltech R&D Ltd Biological products
GB0514779D0 (en) 2005-07-19 2005-08-24 Celltech R&D Ltd Biological products
US8129505B2 (en) 2005-09-14 2012-03-06 Ucb Pharma S.A. Comb polymers
KR101422523B1 (ko) 2005-12-09 2014-07-24 유씨비 파마, 에스.에이. 사람 ｉｌ­6에 특이성을 지니는 항체 분자
GB0614780D0 (en) 2006-07-25 2006-09-06 Ucb Sa Biological products
GB0620729D0 (en) 2006-10-18 2006-11-29 Ucb Sa Biological products
BRPI0809042B1 (pt) 2007-03-22 2021-08-31 Biogen Ma Inc. Proteína de ligação a cd154 isolada, seu uso, e composição
JP2010528664A (ja) * 2007-06-08 2010-08-26 ダウ グローバル テクノロジーズ インコーポレイティド Ｃｈ１ドメインの切断による可溶性抗体断片の発現
GB0717337D0 (en) 2007-09-06 2007-10-17 Ucb Pharma Sa Method of treatment
CN104004088B (zh) 2007-09-26 2017-11-07 Ucb医药有限公司 双特异性抗体融合物
US9086411B2 (en) * 2007-12-27 2015-07-21 Duke University Resin assisted capture of cysteine-modified proteins/peptides and determination of presence and location of modification
GB0800277D0 (en) 2008-01-08 2008-02-13 Imagination Tech Ltd Video motion compensation
GB0807413D0 (en) 2008-04-23 2008-05-28 Ucb Pharma Sa Biological products
GB0900425D0 (en) 2009-01-12 2009-02-11 Ucb Pharma Sa Biological products
CA2751477C (en) 2009-02-17 2019-08-27 Ucb Pharma S.A. Antibody molecules having specificity for human ox40
GB0903207D0 (en) 2009-02-25 2009-04-08 Ucb Pharma Sa Method for expressing multimeric proteins
WO2010097435A1 (en) 2009-02-25 2010-09-02 Ucb Pharma, S.A. Method for producing antibodies
GB0904214D0 (en) 2009-03-11 2009-04-22 Ucb Pharma Sa Biological products
EP2475682B1 (en) 2009-09-10 2018-01-31 UCB Biopharma SPRL Multivalent antibodies
GB201005063D0 (en) 2010-03-25 2010-05-12 Ucb Pharma Sa Biological products
US9234037B2 (en) 2009-10-27 2016-01-12 Ucb Biopharma Sprl Method to generate antibodies to ion channels
GB0922434D0 (en) 2009-12-22 2010-02-03 Ucb Pharma Sa antibodies and fragments thereof
GB0922435D0 (en) 2009-12-22 2010-02-03 Ucb Pharma Sa Method
EP2493926B1 (en) 2009-10-27 2020-03-11 UCB Biopharma SRL Function modifying nav 1.7 antibodies
GB0920127D0 (en) 2009-11-17 2009-12-30 Ucb Pharma Sa Antibodies
GB0920324D0 (en) 2009-11-19 2010-01-06 Ucb Pharma Sa Antibodies
GB201000467D0 (en) 2010-01-12 2010-02-24 Ucb Pharma Sa Antibodies
US8993731B2 (en) 2010-03-11 2015-03-31 Ucb Biopharma Sprl PD-1 antibody
TW201134488A (en) 2010-03-11 2011-10-16 Ucb Pharma Sa PD-1 antibodies
CN102388061A (zh) * 2010-03-17 2012-03-21 松下电器产业株式会社 将由a蛋白或a蛋白的a至e结构域中的至少一个结构域所组成的蛋白质结合到基材上的方法
US8859294B2 (en) * 2010-03-17 2014-10-14 Panasonic Corporation Method for binding a protein consisting of protein A or consisting of at least one domain of the A to E domains of the protein A to the substrate
GB201005064D0 (en) 2010-03-25 2010-05-12 Ucb Pharma Sa Biological products
US10472426B2 (en) 2010-03-25 2019-11-12 Ucb Biopharma Sprl Disulfide stabilized DVD-Ig molecules
LT2663577T (lt) 2011-01-14 2017-07-25 Ucb Biopharma Sprl Antikūnas, surišantis il-17a ir il-17f
WO2013034579A1 (en) 2011-09-05 2013-03-14 Rheinische Friedrich-Wilhelms-Universität Bonn Biosynthetic gene cluster for the production of peptide/protein analogues
KR20140063825A (ko) 2011-09-16 2014-05-27 유씨비 파마, 에스.에이. 클로스트리듐 디피실의 주요 외독소 tcda 및 tcdb에 대한 중화 항체
PT2776466T (pt) 2011-11-11 2017-11-30 Ucb Biopharma Sprl Anticorpos de ligação a albumina e seus fragmentos de ligação
ES2967272T3 (es) 2011-11-30 2024-04-29 Bullerdiek Joern Expresión de miARNs en tejido placentario
ES2721882T3 (es) 2011-12-23 2019-08-06 Pfizer Regiones constantes de anticuerpo modificadas por ingeniería genética para conjugación específica de sitio y procedimientos y usos de las mismas
GB201201332D0 (en) 2012-01-26 2012-03-14 Imp Innovations Ltd Method
GB201208370D0 (en) 2012-05-14 2012-06-27 Ucb Pharma Sa Antibodies
EP2867674B1 (en) 2012-06-28 2018-10-10 UCB Biopharma SPRL A method for identifying compounds of therapeutic interest
EP2759602A1 (en) 2013-01-25 2014-07-30 Charité - Universitätsmedizin Berlin Non-invasive prenatal genetic diagnostic methods
GB201315487D0 (en) 2013-08-30 2013-10-16 Ucb Pharma Sa Antibodies
CN114457044A (zh) 2013-10-25 2022-05-10 普西奥克瑟斯医疗有限公司 武装有异源基因的溶瘤腺病毒
GB201320066D0 (en) 2013-11-13 2013-12-25 Ucb Pharma Sa Biological products
US9914769B2 (en) 2014-07-15 2018-03-13 Kymab Limited Precision medicine for cholesterol treatment
US9045545B1 (en) 2014-07-15 2015-06-02 Kymab Limited Precision medicine by targeting PD-L1 variants for treatment of cancer
US8992927B1 (en) 2014-07-15 2015-03-31 Kymab Limited Targeting human NAV1.7 variants for treatment of pain
US9067998B1 (en) 2014-07-15 2015-06-30 Kymab Limited Targeting PD-1 variants for treatment of cancer
US8986694B1 (en) 2014-07-15 2015-03-24 Kymab Limited Targeting human nav1.7 variants for treatment of pain
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
TW201619188A (zh) 2014-03-05 2016-06-01 優稀美生物醫藥公司 多聚體Ｆｃ蛋白質
GB201406608D0 (en) 2014-04-12 2014-05-28 Psioxus Therapeutics Ltd Virus
GB201409558D0 (en) 2014-05-29 2014-07-16 Ucb Biopharma Sprl Method
GB201411320D0 (en) 2014-06-25 2014-08-06 Ucb Biopharma Sprl Antibody construct
US9139648B1 (en) 2014-07-15 2015-09-22 Kymab Limited Precision medicine by targeting human NAV1.9 variants for treatment of pain
GB201412659D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
GB201412658D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
GB201506869D0 (en) 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method
GB201506870D0 (en) 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method
WO2016176656A2 (en) 2015-04-30 2016-11-03 President And Fellows Of Harvard College Anti-ap2 antibodies and antigen binding agents to treat metabolic disorders
GB201508180D0 (en) 2015-05-13 2015-06-24 Ucb Biopharma Sprl Antibodies
MA47395A (fr) 2015-05-27 2019-12-11 Ucb Biopharma Sprl Méthode pour le traitement d'une maladie neurologique
GB201510758D0 (en) 2015-06-18 2015-08-05 Ucb Biopharma Sprl Novel TNFa structure for use in therapy
CN107849105B (zh) 2015-07-06 2021-09-17 Ucb生物制药有限责任公司 Tau结合抗体
CA2991451A1 (en) 2015-07-06 2017-01-12 Ucb Biopharma Sprl Tau-binding antibodies
GB201601073D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies
GB201601075D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies molecules
GB201601077D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibody molecule
US11142794B2 (en) 2015-10-05 2021-10-12 UCB Biopharma SRL Molecular signatures for use in diagnosis and response to treatment analysis of autoimmune diseases
JP6931648B2 (ja) 2015-10-27 2021-09-08 ユーシービー バイオファルマ エスアールエル 抗ｉｌ−１７ａ／ｆ抗体を用いた治療方法
GB201521393D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
GB201521383D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl And Ucb Celltech Method
GB201521391D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
GB201521382D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
GB201521389D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Method
US20180271998A1 (en) 2015-12-04 2018-09-27 Merrimack Pharmaceuticals, Inc. Disulfide-stabilized fabs
GB201522394D0 (en) 2015-12-18 2016-02-03 Ucb Biopharma Sprl Antibodies
GB201602414D0 (en) 2016-02-10 2016-03-23 Nascient Ltd Biological materials and uses thereof
EP3452506A1 (en) 2016-05-01 2019-03-13 UCB Biopharma SPRL Affinity engineered serum protein carrier binding domain
GB201610198D0 (en) 2016-06-10 2016-07-27 Ucb Biopharma Sprl Anti-ige antibodies
SG10201913858WA (en) 2016-08-26 2020-03-30 Agency Science Tech & Res Macrophage stimulating protein receptor (or ron - recepteur d' origine nantais) antibodies and uses thereof
CN109862912A (zh) 2016-08-29 2019-06-07 皮斯奥克斯治疗公司 携带双特异性T细胞衔接器（BiTE）的腺病毒
GB201616596D0 (en) 2016-09-29 2016-11-16 Nascient Limited Epitope and antibodies
WO2018083248A1 (en) 2016-11-03 2018-05-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
WO2018083258A1 (en) 2016-11-03 2018-05-11 Psioxus Therapeutics Limited Oncolytic adenovirus encoding at least three transgenes
WO2018083257A1 (en) 2016-11-03 2018-05-11 Psioxus Therapeutics Limited Oncolytic adenovirus encoding transgenes
GB201621635D0 (en) 2016-12-19 2017-02-01 Ucb Biopharma Sprl Crystal structure
GB201621728D0 (en) 2016-12-20 2017-02-01 Ucb Biopharma Sprl Methods
US11591398B2 (en) * 2017-01-06 2023-02-28 Crescendo Biologics Limited Single domain antibodies to programmed cell death protein 1 (PD-1)
JP7251725B2 (ja) 2017-01-18 2023-04-04 伸晃化学株式会社 化学物質評価用のデバイス、および、化学物質評価方法
WO2018183366A1 (en) 2017-03-28 2018-10-04 Syndax Pharmaceuticals, Inc. Combination therapies of csf-1r or csf-1 antibodies and a t-cell engaging therapy
KR20240042244A (ko) 2017-05-19 2024-04-01 신닥스 파마슈티컬스, 인크. 조합 요법
HUE063274T2 (hu) 2017-06-01 2024-01-28 Akamis Bio Ltd Onkolitikus vírus és eljárás
WO2019004943A1 (en) 2017-06-30 2019-01-03 Aslan Pharmaceuticals Pte Ltd METHOD OF TREATMENT USING ANTIBODY DIRECTED AGAINST IL-13R
JP2020533404A (ja) 2017-09-05 2020-11-19 グラディエーター バイオサイエンシーズ インコーポレイテッド 細胞内送達法
US11364303B2 (en) 2017-09-29 2022-06-21 Pfizer Inc. Cysteine engineered antibody drug conjugates
CN112004550A (zh) 2017-12-14 2020-11-27 康诺贝林伦瑙有限公司 用于治疗视神经脊髓炎的重组IgG Fc多聚体
GB201802486D0 (en) 2018-02-15 2018-04-04 Ucb Biopharma Sprl Methods
KR20210016390A (ko) 2018-06-01 2021-02-15 노파르티스 아게 Bcma에 대한 결합 분자 및 이의 용도
CA3102743A1 (en) 2018-06-18 2019-12-26 UCB Biopharma SRL Gremlin-1 antagonist for the prevention and treatment of cancer
GB201811368D0 (en) 2018-07-11 2018-08-29 Ucb Biopharma Sprl Antibody
KR20210044243A (ko) 2018-08-13 2021-04-22 인히브릭스, 인크. Ox40 결합 폴리펩티드 및 이의 용도
JP2022512713A (ja) 2018-10-16 2022-02-07 ユーシービー バイオファルマ エスアールエル 重症筋無力症の治療方法
GB201817311D0 (en) 2018-10-24 2018-12-05 Ucb Biopharma Sprl Antibodies
GB201817309D0 (en) 2018-10-24 2018-12-05 Ucb Biopharma Sprl Antibodies
GB201900732D0 (en) 2019-01-18 2019-03-06 Ucb Biopharma Sprl Antibodies
SG11202109545VA (en) 2019-03-26 2021-10-28 Aslan Pharmaceuticals Pte Ltd Treatment employing anti-il-13r antibody or binding fragment thereof
US20230071196A1 (en) 2019-05-21 2023-03-09 Novartis Ag Variant cd58 domains and uses thereof
EP3972634A2 (en) 2019-05-21 2022-03-30 Novartis AG Trispecific binding molecules against bcma and uses thereof
SG11202111281TA (en) 2019-05-21 2021-12-30 Novartis Ag Cd19 binding molecules and uses thereof
JP2022543669A (ja) 2019-08-08 2022-10-13 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 新規抗原結合分子フォーマット
EP4028415A1 (en) 2019-09-13 2022-07-20 CSL Behring Lengnau AG Recombinant igg fc multimers for the treatment of immune complex-mediated kidney disorders
JP2022553830A (ja) 2019-11-05 2022-12-26 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｎ末端ｓｃＦｖ多重特異性結合分子
GB201917480D0 (en) 2019-11-29 2020-01-15 Univ Oxford Innovation Ltd Antibodies
GB201919061D0 (en) 2019-12-20 2020-02-05 Ucb Biopharma Sprl Multi-specific antibody
GB201919062D0 (en) 2019-12-20 2020-02-05 Ucb Biopharma Sprl Antibody
BR112022012112A2 (pt) 2019-12-20 2022-09-06 Regeneron Pharma Agonistas de il2 e métodos de uso dos mesmos
GB202001447D0 (en) 2020-02-03 2020-03-18 Ucb Biopharma Sprl Antibodies
WO2021160267A1 (en) 2020-02-13 2021-08-19 UCB Biopharma SRL Bispecific antibodies against cd9 and cd7
EP4103610A1 (en) 2020-02-13 2022-12-21 UCB Biopharma SRL Anti cd44-ctla4 bispecific antibodies
WO2021160265A1 (en) 2020-02-13 2021-08-19 UCB Biopharma SRL Bispecific antibodies against cd9 and cd137
WO2021160268A1 (en) 2020-02-13 2021-08-19 UCB Biopharma SRL Bispecific antibodies against cd9
WO2021160266A1 (en) 2020-02-13 2021-08-19 UCB Biopharma SRL Bispecific antibodies binding hvem and cd9
BR112022016326A2 (pt) 2020-02-21 2022-10-11 Jiangsu Hengrui Pharmaceuticals Co Ltd Anticorpo anti-il-2, e fragmento de ligação ao antígeno do mesmo e uso médico do mesmo
KR20220160069A (ko) 2020-03-27 2022-12-05 유씨비 바이오파마 에스알엘 자율적 노브 도메인 펩티드
WO2021195513A1 (en) 2020-03-27 2021-09-30 Novartis Ag Bispecific combination therapy for treating proliferative diseases and autoimmune disorders
US20230176071A1 (en) 2020-05-08 2023-06-08 UCB Biopharma SRL Arrays and methods for identifying binding sites on a protein
CA3183151A1 (en) 2020-05-12 2021-11-18 Regeneron Pharmaceuticals, Inc. Novel il10 agonists and methods of use thereof
EP4151655A1 (en) 2020-05-14 2023-03-22 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Anti-cd25 antibodies, antigen-binding fragments thereof, and medical uses thereof
JP2023532251A (ja) 2020-07-02 2023-07-27 北京拓界生物医薬科技有限公司 抗ＦＸＩ／ＦＸＩａ抗体、その抗原結合断片と医薬用途
US20230405138A1 (en) 2020-07-27 2023-12-21 Tuojie Biotech (Shanghai) Co., Ltd. Anti-cd79b antibody-drug conjugate, and preparation method therefor and pharmaceutical use thereof
US11926667B2 (en) 2020-10-13 2024-03-12 Janssen Biotech, Inc. Bioengineered T cell mediated immunity, materials and other methods for modulating cluster of differentiation IV and/or VIII
WO2022079036A1 (en) 2020-10-13 2022-04-21 Almirall, S.A. Bispecific molecules and methods of treatment using the same
CA3198049A1 (en) 2020-10-15 2022-04-21 UCB Biopharma SRL Binding molecules that multimerise cd45
CA3199839A1 (en) 2020-11-06 2022-05-12 Novartis Ag Anti-cd19 agent and b cell targeting agent combination therapy for treating b cell malignancies
WO2022097060A1 (en) 2020-11-06 2022-05-12 Novartis Ag Cd19 binding molecules and uses thereof
EP4255925A1 (en) 2020-12-07 2023-10-11 UCB Biopharma SRL Antibodies against interleukin-22
KR20230117588A (ko) 2020-12-07 2023-08-08 유씨비 바이오파마 에스알엘 다중특이적 항체 및 항체 조합
GB202102227D0 (en) 2021-02-17 2021-03-31 UCB Biopharma SRL Antibodies
CA3216034A1 (en) 2021-04-25 2022-11-03 Xiaofeng Yang Anti-masp2 antibody, antigen-binding fragment thereof and medical use thereof
CA3218933A1 (en) 2021-05-03 2022-11-10 UCB Biopharma SRL Antibodies
JP2024517844A (ja) 2021-05-04 2024-04-23 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 多重特異性ｆｇｆ２１受容体アゴニスト及びそれらの使用
BR112023026111A2 (pt) 2021-06-28 2024-03-05 Jiangsu Hengrui Pharmaceuticals Co Ltd Anticorpo anti-cd40, fragmento de ligação ao antígeno e uso médico do mesmo
WO2023285878A1 (en) 2021-07-13 2023-01-19 Aviation-Ophthalmology Methods for detecting, treating, and preventing gpr68-mediated ocular diseases, disorders, and conditions
TW202321282A (zh) 2021-07-19 2023-06-01 美商再生元醫藥公司 Il12受體促效劑及其使用方法
US20230190799A1 (en) * 2021-07-21 2023-06-22 City Of Hope Chimeric antigen receptor t cells targeting cea and anti-cea-il2 immunocytokines for cancer therapy
AU2022331241A1 (en) 2021-08-16 2024-03-28 Regeneron Pharmaceuticals, Inc. Novel il27 receptor agonists and methods of use thereof
GB202111905D0 (en) 2021-08-19 2021-10-06 UCB Biopharma SRL Antibodies
EP4393949A1 (en) 2021-08-25 2024-07-03 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Pharmaceutical composition containing fusion protein
WO2023040945A1 (zh) 2021-09-15 2023-03-23 江苏恒瑞医药股份有限公司 特异性结合pd-1的蛋白及其医药用途
TW202333784A (zh) 2021-10-29 2023-09-01 新加坡商亞獅康私人有限公司 抗ｉｌ１３ｒ抗體調配物
CA3238029A1 (en) 2021-11-11 2023-05-19 Regeneron Pharmaceuticals, Inc. Cd20-pd1 binding molecules and methods of use thereof
WO2023140780A1 (en) 2022-01-24 2023-07-27 Aslan Pharmaceuticals Pte Ltd. Method of treating inflammatory disease
TW202337905A (zh) 2022-02-23 2023-10-01 新加坡商亞獅康私人有限公司 抗il13r抗體之糖基化形式
GB202205200D0 (en) 2022-04-08 2022-05-25 Ucb Biopharma Sprl Combination with chemotherapy
GB202205203D0 (en) 2022-04-08 2022-05-25 UCB Biopharma SRL Combination with inhibitor
WO2023220647A1 (en) 2022-05-11 2023-11-16 Regeneron Pharmaceuticals, Inc. Multispecific binding molecule proproteins and uses thereof
WO2023230594A1 (en) 2022-05-27 2023-11-30 Regeneron Pharmaceuticals, Inc. Interleukin-2 proproteins and uses thereof
WO2023235848A1 (en) 2022-06-04 2023-12-07 Regeneron Pharmaceuticals, Inc. Interleukin-2 proproteins and uses thereof
WO2024040247A1 (en) 2022-08-18 2024-02-22 Regeneron Pharmaceuticals, Inc. Interferon proproteins and uses thereof
US20240067691A1 (en) 2022-08-18 2024-02-29 Regeneron Pharmaceuticals, Inc. Interferon receptor agonists and uses thereof
WO2024043837A1 (en) 2022-08-26 2024-02-29 Aslan Pharmaceuticals Pte Ltd High concentration anti-il13r antibody formulation
WO2024115393A1 (en) 2022-11-28 2024-06-06 UCB Biopharma SRL Treatment of fibromyalgia
WO2024130175A2 (en) 2022-12-16 2024-06-20 Regeneron Pharmaceuticals, Inc. Antigen-binding molecules that bind to aav particles and uses

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8720833D0 (en) 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
CA2116774C (en) 1991-09-19 2003-11-11 Paul J. Carter Expression in e. coli antibody fragments having at least a cysteine present as a free thiol. use for the production of bifunctional f(ab') 2 antibodies
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
AU2003217912A1 (en) * 2002-03-01 2003-09-16 Xencor Antibody optimization

Also Published As

Publication number Publication date
EP1644412B1 (en) 2015-09-09
ES2551439T5 (es) 2018-11-08
WO2005003169A2 (en) 2005-01-13
WO2005003169A3 (en) 2005-05-06
EP1644412B2 (en) 2018-08-08
PT1644412E (pt) 2015-12-23
US20060257394A1 (en) 2006-11-16
PL1644412T5 (pl) 2019-01-31
US7989594B2 (en) 2011-08-02
JP2007536898A (ja) 2007-12-20
SI1644412T2 (sl) 2018-11-30
HRP20151252T1 (en) 2015-12-18
CY1116913T1 (el) 2017-04-05
HUE026278T2 (en) 2016-05-30
DK1644412T4 (en) 2018-11-12
AU2004253738A1 (en) 2005-01-13
CA2527020A1 (en) 2005-01-13
EP1644412A2 (en) 2006-04-12
HRP20151252T4 (hr) 2018-11-30
SI1644412T1 (sl) 2015-12-31
DK1644412T3 (en) 2015-12-14
ES2551439T3 (es) 2015-11-19

Similar Documents

Publication Publication Date Title
HRP20151252T4 (hr) Modificirani fab ulomci protutijela
PT1599504E (pt) Anticorpo modificado
IL175710A0 (en) Anti-mpl antibody
IL227753A0 (en) A qualified antibody or antibody residue
EP1494693A4 (en) SPECIFIC ANTIBODIES TO CRIPTO
IL175608A0 (en) Antibodies
AU2003264009A8 (en) Humanized rabbit antibodies
PL375405A1 (pl) Przeciwciała
IL176940A (en) An isolated antibody or antigen-binding fragment thereof
EP1648512A4 (en) ANTI-CD19 ANTIBODIES
EP1693385A4 (en) ANTI-CD47 ANTIBODIES HUMANIZED
AU2003217912A8 (en) Antibody optimization
IL173557A0 (en) Variable antibodies
EP1677112A4 (en) IMMUNE TEST
EP1594888A4 (en) TOLERANCE-INDUCED TARGET PRODUCTION OF ANTIBODIES
EP1598368A4 (en) ANTI-PCI neutralizing ANTIBODY
GB0305448D0 (en) Immunoassay
GB0306618D0 (en) Antibody
EP1712564A4 (en) MONOCLONAL ANTIBODY ANTI-NC1
EP1559725A4 (en) ANTIBODY WITH ANTIGENIC RECOGNITION
GB0226878D0 (en) Antibodies
AU2003236346A1 (en) Monoclonal antibody neutralizing megsin
HK1209139A1 (en) Modified antibody
GB0415644D0 (en) Monoclonal antibody
GB0325391D0 (en) Human monoclonal antibodies